UBS Group Lowers Envista (NYSE:NVST) Price Target to $21.00

Envista (NYSE:NVST) had its target price lowered by UBS Group from $23.00 to $21.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other equities analysts have also recently weighed in on NVST. Mizuho initiated coverage on shares of Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price objective for the company. Morgan Stanley reduced their price objective on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Wells Fargo & Company upped their price objective on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 6th. Jefferies Financial Group upped their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.18.

Envista Stock Performance

Shares of NYSE NVST opened at $16.73 on Monday. The company’s fifty day moving average price is $20.10 and its 200 day moving average price is $19.67. Envista has a 1 year low of $15.15 and a 1 year high of $23.00. The company has a market capitalization of $2.88 billion, a PE ratio of -2.58, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, research analysts predict that Envista will post 1 earnings per share for the current year.

Institutional Investors Weigh In On Envista

A number of hedge funds have recently modified their holdings of NVST. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Envista by 11.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,314 shares of the company’s stock valued at $303,000 after purchasing an additional 1,538 shares during the period. US Bancorp DE boosted its stake in Envista by 150.6% during the third quarter. US Bancorp DE now owns 4,971 shares of the company’s stock worth $98,000 after buying an additional 2,987 shares during the period. Assetmark Inc. boosted its stake in Envista by 5.9% during the third quarter. Assetmark Inc. now owns 38,641 shares of the company’s stock worth $764,000 after buying an additional 2,152 shares during the period. Covestor Ltd boosted its stake in Envista by 34.2% during the third quarter. Covestor Ltd now owns 6,359 shares of the company’s stock worth $125,000 after buying an additional 1,621 shares during the period. Finally, State of New Jersey Common Pension Fund D boosted its stake in Envista by 5.4% during the third quarter. State of New Jersey Common Pension Fund D now owns 107,686 shares of the company’s stock worth $2,128,000 after buying an additional 5,497 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.